Rapamycin and mTOR: The Biology Behind TRIAD
Rapamycin targets a nutrient-sensing pathway called mTOR that appears again and again in aging research. Here is what that pathway does, why scientists are interested, and what is and is not known in dogs.
A pathway that keeps showing up
If you read aging research long enough, one name appears again and again: mTOR. It is a nutrient-sensing pathway — a cellular switch that decides whether a cell should grow or maintain itself.
When nutrients are abundant, mTOR promotes growth. When nutrients are scarce, or when a drug like rapamycin is present, the pathway shifts toward maintenance, repair and recycling within the cell.
That shift is why mTOR sits at the center of so much aging research.
> Pawformance Labs is not affiliated with, sponsored by, endorsed by, or in contact with TRIAD, the Dog Aging Project, or their research teams. We did not conduct this research. We cannot enroll a dog, provide rapamycin, or speak on their behalf. Everything here is our own independent, informational summary of publicly available research. Nothing on this page is a suggestion to obtain or give any drug to a dog.
Why the switch matters for aging
Aging, at the cellular level, involves a gradual imbalance: less efficient repair, more accumulated damage, slower turnover of worn components. A pathway that can tilt the balance back toward maintenance is interesting to anyone studying why bodies decline over time.
In laboratory animals — yeast, worms, flies, mice — inhibiting mTOR has been associated with extended lifespan and delayed age-related decline. The effect is consistent enough across species that researchers wanted to ask the question in dogs.
What rapamycin actually does
Rapamycin is a small-molecule drug, originally discovered in soil bacteria, that inhibits mTOR. It is not a peptide — which is why it belongs in this geroscience section rather than in our Peptide Science collection.
It is already used in human medicine for specific indications, so its pharmacology is reasonably well understood. That matters: researchers are not starting from scratch with an unknown compound. They know what it does, what it interacts with, and what its risks are.
What is and is not known in dogs
The biology is plausible: dogs have the mTOR pathway, it functions similarly, and the rationale for studying rapamycin in aging dogs is built on cross-species evidence that is genuinely consistent.
The outcomes are not yet known: whether inhibiting mTOR in companion dogs actually extends lifespan or preserves healthspan is what TRIAD is designed to find out. No result has been published.
That gap — between a plausible mechanism and a demonstrated outcome — is exactly why we classify this as mechanistic only. The pathway is real and interesting. The benefit in dogs is still a question, not an answer.
Why we follow it
mTOR is one of the most important threads in aging research. If TRIAD shows that influencing it changes how dogs age, it would open a door that has never been opened in companion animals. If it does not, the negative result is also valuable — it would tell us that a pathway that works in the laboratory does not translate to the living room.
Either way, the question is worth asking, and worth following honestly.
Learn more at the [official TRIAD program page](https://dogagingproject.org/triad).
Keep going